Introduction
Onychomycosis, a chronic nail infection caused by dermatophytes, yeasts or non-dermatophyte molds, is one of the most common dermatological diseases worldwide [1, 2] . This infection is the most frequent nail disorder in adults, accounting for up to 50% of all nail diseases [3] .
Despite recent advances in the development of antifungal drugs and therapy, onychomycosis is still diffi cult to treat [4] . Conventional treatments frequently fail and it has been proposed that many factors, such as age, peripheral vascular disease, nail growth, poor drug penetration into the nail, extent of nail lesions and fungal growth patterns (i.e., presence of vegetative cells as well as spores) adversely affect clinical outcomes [5] .
Here we determined the MICs of fi ve antifungal agents against 100 clinical isolates (70 dermatophytes and 30 nondermatophyte molds) using CLSI M38-A2 for fi lamentous fungi and Eucast Document 7.1 for yeasts [10] .
Materials and methods

Isolates
A total of 100 clinical strains were studied including Trichophyton rubrum ( n ϭ 35), T. mentagrophytes ( n ϭ 29), Microsporum canis ( n ϭ 3), Epidermophyton fl occosum ( n ϭ 3); and non-dermatophyte molds, i.e., Scopulariopsis brevicaulis ( n ϭ 14), Acremonium spp. ( n ϭ 7), and Aspergillus spp. ( n ϭ 9). Each isolate was recovered from specimens of patients with toenail onychomycosis that were attended at the Podiatric Clinic of the University of Barcelona. Nail samples were inoculated onto Sabouraud dextrose agar (SDA; Scharlau, Barcelona. Spain) supplemented with 20 mg/ml of chloramphenicol to inhibit bacterial growth. A replica was done on plates of dermatophyte test medium (DTM) prepared in house by adding 500 μ g/ml cycloheximide (Sigma-Aldrich, Spain) and 200 μ g/ml phenol red (Sigma-Aldrich, Spain) to the base SDA. Plates were observed each week and the fungi recovered were identifi ed using standard microscopic methods and urease production tests [11] . Isolated fungi were subcultured onto antimicrobial-free potato dextrose agar (PDA; Scharlab, Barcelona. Spain) and incubated for 3 weeks at 28 ° C to prepare inocula. Fungi were stored at room temperature (23 -25 ° C) on PDA slants [12] . The results for the reference QC strain C. albicans ATCC 90028 were within the acceptable ranges recommended by the Clinical and Laboratory Standards Institute (CLSI) (data not shown) [13, 14] . The medium used for broth microdilution susceptibility testing was RPMI 1640 (Sigma-Aldrich, Spain) with L-glutamine but without sodium bicarbonate, and buffered with HEPES 25mM (Sigma-Aldrich, Spain). The medium was sterilized by fi ltration.
Materials for antimicrobial susceptibility testing
For in vitro testing, we used the following antifungal agents, provided by the manufacturers as assay powders; ciclopiroxolamine (Laboratorios Ferrer, Spain), eberconazole (Laboratorios Salvat, Spain), fl uconazole, itraconazole and terbinafi ne (Sigma-Aldrich, Spain). All drugs were dissolved in 100% dimethyl sulfoxide, followed by further dilutions in RPMI 1640 medium to yield twice the fi nal strength required for the test. For itraconazole, ciclopirox and eberconazol, fi nal concentrations ranged from 0.016 -8,000 μ g/ml, for fl uconazole from 0.063 -32,000 μ g/ml and for terbinafi ne from 0.004 -2,000 μ g/ml.
Drug dilution plates were stored at Ϫ 70 ° C for up to a maximum of 3 months.
Inoculum preparation
To prepare inocula, the fungi were subcultured onto potato dextrose agar (PDA, Scharlau, Barcelona, Spain) and incubated at 28 ° C for 3 weeks. The plates were then covered with 10 ml of sterile distilled water and conidia were collected by scraping the colonies with the tip of a sterile Pasteur pipette. The resulting mixture of conidia and hyphal fragments was withdrawn and transferred to a sterile tube. Heavy particles were allowed to settle for 5 -15 min, and the upper suspension was collected and homogenized.
The suspension obtained was then fi ltered once through sterile gauze folded three times to remove hyphal fragments [15] and transferred to a sterile tube. We compared two methods of inoculum preparation, namely hematocytometer counts and spectrophotometric readings. We obtained a mixture of conidia and adjusted it to 0.5 ϫ 10 5 -5 ϫ 10 5 spores/ml spectrophotometrically [16] at 546 nm wavelength. Quantitative cultures were prepared by plating 10 μ l of the adjusted inoculum on SDA-chloramphenicol agar. The plates were incubated at 30 ° C and observed daily for the presence of growth.
The volume of the inoculum was diluted in RPMI 1640 to the desired concentration of 0.5 ϫ 10 3 -0.5 ϫ 10 4 ufc/ml.
Test procedure
All tests were performed in round-bottomed 96-well microplates. Aliquots of 100 μ l of the two-fold drug dilutions were transferred into the microplate wells by means of a multichannel pipette. Each well was then inoculated with 100 μ l of the diluted inoculum suspension. For each test plate, two drug-free growth controls were included, one with the media alone (growth control) and the other with media containing an equivalent amount of solvent used to dissolve the drugs (solvent control).
Growth and sterility controls were included for each assay and tests were performed in triplicate. The plates were incubated at 30 ° C and read after 3 -5 days of incubation. Growth in the control and test wells was checked every day. The incubation was prolonged until growth was detected [17] .
Reading and interpretation of MICs
Endpoint values were determined by visual comparison of wells and controls and were established as the lowest concentrations giving 50% growth inhibition. Geometric mean and minimum inhibitory concentration (MIC) ranges were determined to allow comparisons of drug activities. as they are affected by the testing conditions [18, 20] . The strong antifungal activity of terbinafi ne against dermatophytes has been reported by other authors [16, 21, 22] .
Eberconazole is a novel topical imidazole with a mode of action similar to that of other azole antifungal agents and has shown potent in vivo and in vitro activity against dermatophytes.
Although the association of non-dermatophyte fi lamentous fungi with onychomycosis is unclear, we cannot rule out that the clinical evolution of this infection may worsen depending on the species involved.
Fern á ndez-Torres et al . evaluated an agar dilution method in studies of 100 strains of T. rubrum . They used In addition, MIC values at which 50% and 90% of isolates were inhibited (MIC 50 and MIC 90 respectively) were recorded. All isolates when cultivated in the absence of antifungals, produced clearly detectable growth after 5 days of incubation.
Results
We determined the in vitro susceptibility of the dermatophytes most commonly isolated from our patients to fi ve antifungal agents. While in general, all drugs except fl uconazole showed activity, eberconazole gave the lowest geometric mean MIC (0.113 μ g/ml) of the drugs tested and was active against most of the test isolates assayed.
The activity of both terbinafi ne and eberconazole was signifi cantly higher than that of the other drugs, especially against T. mentagrophytes and T. rubrum . The highest MIC value ( Ն 32 μ g/ml) for isolates of these two species was found with fl uconazole (Table 1) .
Similar results were obtained by other authors independently of the experimental parameters used. These data confi rm the resistance of dermatophyte species to fl uconazole and contradict the cure rates achieved in patients with dermatophytosis treated with this drug [18] .
No signifi cant differences in susceptibility were observed between M. canis and E. fl occosum for any of the tested drugs.
Discussion
In vitro antifungal susceptibility testing of dermatophytes is still technically diffi cult to conduct as a result of their growth and spore formation characteristics. Repeated subcultures often make it extremely hard to prepare conidial inocula [19] , although in this study we determined the fungal MICs immediately after the isolate in PDA cultures. The parameters employed in this investigation for evaluating the in vitro susceptibility of dermatophytes to antifungal agents proved to be suitable and reliable. Furthermore, they may provide insights for the development of a standard assay. While the MIC endpoints and clinical significance of the susceptibility testing of the remaining fungi and antifungal drugs remain unclear, intense efforts to overcome the present drawbacks and limitations are currently focused on modifi cations of available methods, as well as the development of alternative techniques [20] .
The predictive value of the MICs obtained using these techniques is unknown due to the fact that the limited number of studies of in vivo -in vitro correlation have involved only a few species and a few antifungal drugs. Consequently, concise endpoints are not available. Several collaborative studies involving the testing of fi lamentous fungi have demonstrated that azole MICs are extremely variable Table 1 In vitro susceptibility of 100 isolates to the fi ve drugs tested by a microdilution method.
MIC( μ g/ml)
Genus and species n Antifungal GM Range MIC 50 four antifungal drugs commonly administered to treat dermatophytoses (i.e., clotrimazole, ketoconazole, itraconazole and terbinafi ne) and also compared the results with the MICs obtained by a microdilution method [18, 22] . Their results revealed higher MICs for the assayed azoles with the agar dilution method while MIC values remained low in tests with the microdilution technique. Thus, the latter appeared to be more predictive of clinical outcome. Many species and antifungal drugs have been assayed using this method. In addition, it is technically less cumbersome than other approaches. We observed high in vitro activity of itraconazole and eberconazole while terbinafi ne and ciclopirox showed slightly higher activity than that reported by other authors. Among the group of azole derivatives, fl uconazole was found to have the lowest antifungal activity. This observation is consistent with the high MICs described by other authors when comparing different methods. These results could refl ect the unsuccessful therapeutic effect that we obtained with this antifungal agent (data not shown).
Certain factors, such as temperature, incubation period, MIC endpoints, culture medium or kind (microconidial or hyphae) and size of inocula, infl uence the determination of the susceptibility of yeasts and fi lamentous fungi to antifungal agents. A multicentric study developed to determine the optimal parameters for the use of the microdilution assay with dermatophytes concluded that the optimal reproducibility conditions were as follows; incubation temperature 28 ° C, 7 days of incubation, inocula of 10 4 microconidia/ml and endpoint at 100% of growth inhibition. Other variables such as the color of the spores can also infl uence the OD values [23] . The comparison of hematocytometer counts and spectrophotometric readings in the preparation of inocula indicate that there is no signifi cant difference between the two approaches. Counting with a hematocytometer is a universal procedure that is not affected by the color of the strain or by spore size. Moreover, both the CLSI and the EUAST-AFST recommend that inocula standardization be based on the determination of cell density by spectrophotometry [24] .
In summary, our study confi rms previous work on in vitro antifungal susceptibility patterns and reports a novel modifi ed method for testing dermatophytes. However, because MIC endpoints have not yet been established for onychomycosis, it remains unclear whether the in vitro activity of antifungal drugs is predictive of the clinical outcome.
